Arsenic (+3 oxidation state) methyltransferase gene polymorphisms and expression on bladder cancer

Inorganic arsenic (iAs) is a recognized environment-related factor for
bladder cancer (BCa). Arsenic (+3 oxidation state) methyltransferase
(AS3MT) gene might influence BCa by regulating iAs
metabolism. The objectives of the present study were to systematically
review eligible case-control studies about
AS3MT polymorphisms and BCa and to
further compare the genotype distribution and allele distribution
between BCa patients and controls by meta-analysis for humans. Besides, to
clarify the effects of AS3MT expression on BCa clinical outcomes and
survival time, we also conducted a series of analyses based on The Cancer
Genome Atlas (TCGA) dataset. Databases were systematically retrieved and
we applied Stata software to perform meta-analysis. The registration of
this study protocol is at PROSPERO and ID is CRD42019133947. Five
articles were recruited and pooled results demonstrated
that rs3740393 and rs11191438 polymorphisms were related to BCa
risk in overall population (P<0.05) in the overall
population. In addition, GG and GC genotypes in rs3740393 and GG
genotype in rs11191438 might be the susceptibility genotypes for BCa.
Results based on 168 BCa samples from TGCA indicated that
patients with higher expression of AS3MT had poor overall
survival time and AS3MT expression is an
independent indicator for BCa survival. This study
identified that AS3MT polymorphisms could affect BCa
risk and AS3MT expression was pivotal in prognosis of BCa.